{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=34", "query": { "condition": "Pharmacokinetics and Pharmacodynamics", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 2339, "total_pages": 234, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T22:53:18.520Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02009761", "title": "Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Purpura, Thrombocytopenic, Idiopathic" ], "interventions": [ { "name": "BI 655064", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2013-12-18", "completion_date": "2016-04-26", "has_results": true, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-10-16T22:53:18.520Z", "location_count": 2, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009761" }, { "nct_id": "NCT04370873", "title": "Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Hypertension" ], "interventions": [ { "name": "Frespaciguat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 22, "start_date": "2020-06-05", "completion_date": "2022-01-12", "has_results": true, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-10-16T22:53:18.520Z", "location_count": 6, "location_summary": "Lexington, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 2 more", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04370873" }, { "nct_id": "NCT07318805", "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer (HR+/ HER2-)", "Colorectal Cancer", "Metastatic Colorectal Adenocarcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PF-08032562", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2025-12-23", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-16T22:53:18.520Z", "location_count": 13, "location_summary": "Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Long Island City", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07318805" }, { "nct_id": "NCT06795412", "title": "Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "PYX-201", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pyxis Oncology, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2025-04-15", "completion_date": "2027-12-06", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-16T22:53:18.520Z", "location_count": 13, "location_summary": "San Diego, California • Santa Monica, California • Tampa, Florida + 8 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06795412" }, { "nct_id": "NCT00207051", "title": "BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Brivanib + Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2006-01", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2011-01-25", "last_synced_at": "2026-10-16T22:53:18.520Z", "location_count": 5, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00207051" }, { "nct_id": "NCT01462851", "title": "A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-05297909 25 mg", "type": "DRUG" }, { "name": "PF-05297909 100 mg", "type": "DRUG" }, { "name": "PF-05297909 250 mg", "type": "DRUG" }, { "name": "PF-05297909 525 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 51, "start_date": "2011-09", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2012-03-13", "last_synced_at": "2026-10-16T22:53:18.520Z", "location_count": 2, "location_summary": "Glendale, California • New Haven, Connecticut", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01462851" }, { "nct_id": "NCT01405651", "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Subjects" ], "interventions": [ { "name": "ONO-6950", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ono Pharma USA Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2011-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-06-14", "last_synced_at": "2026-10-16T22:53:18.520Z", "location_count": 1, "location_summary": "Miramar, Florida", "locations": [ { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01405651" }, { "nct_id": "NCT05151731", "title": "A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Vamikibart", "type": "DRUG" }, { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 394, "start_date": "2021-12-31", "completion_date": "2025-04-21", "has_results": true, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-16T22:53:18.520Z", "location_count": 36, "location_summary": "Arcadia, California • Poway, California • Sacramento, California + 33 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Poway", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05151731" }, { "nct_id": "NCT03335553", "title": "A Study of Experimental Medication BMS-986235 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mediators of Inflammation" ], "interventions": [ { "name": "BMS-986235", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 122, "start_date": "2017-11-15", "completion_date": "2021-07-02", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-16T22:53:18.520Z", "location_count": 2, "location_summary": "Anaheim, California • Salt Lake City, Utah", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03335553" }, { "nct_id": "NCT07190469", "title": "PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer (TNBC)", "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "PQ203", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ProteinQure Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-09-16", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-16T22:53:18.520Z", "location_count": 3, "location_summary": "Houston, Texas • San Antonio, Texas • West Valley City, Utah", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07190469" } ] }